-
公开(公告)号：US07708986B2
公开(公告)日：2010-05-04
申请号：US11483017
申请日：2006-07-07
Applicant: Erlinda M. Gordon , Frederick L. Hall
Inventor： Erlinda M. Gordon , Frederick L. Hall
CPC classification number: A61K47/4813 , A61K38/1709 , A61K38/191 , A61K38/193 , A61K38/2006 , A61K38/2013 , A61K38/2046 , A61K38/217 , A61K47/555 , A61K48/00 , C12N15/86 , C12N2740/13043 , C12N2740/13045 , C12N2810/857
Abstract: This invention provides compositions and methods for treating cancer. More specifically this invention is directed to a targeted retroviral vector comprising a cytokine gene that can be administered either alone or in combination with a targeted retroviral vector comprising a cytocidal gene for treating cancer in a subject. Also provided are a kit or drug delivery system comprising the compositions for use in the methods described.
Abstract translation: 本发明提供了治疗癌症的组合物和方法。 更具体地，本发明涉及包含细胞因子基因的靶向的逆转录病毒载体，其可以单独施用或与包含用于治疗受试者中的癌症的杀细胞基因的靶向逆转录病毒载体组合施用。 还提供了包含用于所述方法的组合物的试剂盒或药物递送系统。
-
2.发明申请MATRIX-TARGETED FUSION POLYPEPTIDES FOR TISSUE REGENERATION AND WOUND HEALING 审中-公开用于组织再生和创伤治疗的基质定向融合多聚体公开(公告)号：US20090093407A1
公开(公告)日：2009-04-09
申请号：US12207457
申请日：2008-09-09
Applicant: Frederick L. Hall , Erlinda M. Gordon , Robert W. Beart , Marcell Nimni
Inventor： Frederick L. Hall , Erlinda M. Gordon , Robert W. Beart , Marcell Nimni
CPC classification number: C12N5/0679 , A61K35/12 , A61K38/00 , A61K48/00 , C07K14/485 , C07K14/755 , C07K2319/00
Abstract: The present invention relates to compositions and methods for promoting tissue repair and regeneration. The invention provides a fusion polypeptide useful for targeting tissues for regeneration and methods of use therefore.
Abstract translation: 本发明涉及用于促进组织修复和再生的组合物和方法。 本发明提供了可用于靶向用于再生的组织的融合多肽和因此使用的方法。
-
公开(公告)号：US08052966B2
公开(公告)日：2011-11-08
申请号：US10829926
申请日：2004-04-21
Applicant: Frederick L. Hall , Erlinda M. Gordon
Inventor： Frederick L. Hall , Erlinda M. Gordon
CPC classification number: C07K14/4738 , A61K48/00 , C12N15/85 , C12N15/86 , C12N2740/13043 , C12N2740/13045 , C12N2800/108 , C12N2810/85
Abstract: Methods and compositions for producing targeted delivery vectors are provided. Such vectors are useful for treating neoplastic disorders. Also provided are protocols for administering targeted delivery vectors in a clinical setting such that a therapeutic effect is achieved.
Abstract translation: 提供了用于产生靶向递送载体的方法和组合物。 这样的载体可用于治疗肿瘤性疾病。 还提供了用于在临床环境中施用靶向递送载体的方案，使得实现治疗效果。
-
公开(公告)号：US07605142B2
公开(公告)日：2009-10-20
申请号：US11553416
申请日：2006-10-26
Applicant: Erlinda M. Gordon , Frederick L. Hall , W. French Anderson
Inventor： Erlinda M. Gordon , Frederick L. Hall , W. French Anderson
IPC: C08B11/193
CPC classification number: C12N15/113 , A01K67/0271 , A01K2207/15 , A01K2217/00 , A01K2217/058 , A01K2227/105 , A01K2267/0331 , A61K38/00 , A61K48/00 , C07K14/4738 , C07K14/4746 , C07K16/18 , C12N2799/027 , G01N2333/4739
Abstract: A method of treating a tumor (in particular osteosarcoma or Ewing's sarcoma) in a host by administering to a host or to the tumor cells an agent which inhibits cyclin G1 protein in an amount effective to inhibit cyclin G1 protein in tumor cells of the host. The agent may be an antisense polynucleotide which is complementary to at least a portion of a polynucleotide encoding cyclin G1 protein, or an antibody or fragment or derivative thereof which recognizes cyclin G1 protein. Also contemplated within the scope of the present invention are (i) the immortalization of cell lines by transducing cells with a polynucleotide encoding cyclin G1 protein; (ii) increasing the receptiveness of cells to retroviral infection by transducing cells with a polynucleotide encoding cyclin G1 protein; and (iii) the detection of cancer by detecting cyclin G1 protein or a polynucleotide encoding cyclin G1 protein in cells. In addition, the present invention provides expression vehicles, such as, for example, retroviral vectors and adenoviral vectors, which include polynucleotides which encode agents which inhibit cyclin G1 protein, and expression vehicles which include a polynucleotide encoding cyclin G1 protein.
Abstract translation: 通过向宿主或肿瘤细胞施用以有效抑制宿主肿瘤细胞中的细胞周期蛋白G1蛋白的量的细胞周期蛋白G1蛋白质的药物来治疗宿主中的肿瘤（特别是骨肉瘤或尤因氏肉瘤）的方法。 该试剂可以是与编码细胞周期蛋白G1蛋白的多核苷酸的至少一部分互补的反义多核苷酸，或其识别细胞周期蛋白G1蛋白的抗体或其片段或衍生物。 在本发明的范围内也考虑到：（i）通过用编码细胞周期蛋白G1蛋白的多核苷酸转导细胞来使细胞系永生化; （ii）通过用编码细胞周期蛋白G1蛋白的多核苷酸转导细胞来增加细胞对逆转录病毒感染的接受性; 和（iii）通过检测细胞周期蛋白G1蛋白或编码细胞周期蛋白G1蛋白的多核苷酸来检测癌症。 此外，本发明提供表达载体，例如逆转录病毒载体和腺病毒载体，其包括编码抑制细胞周期蛋白G1蛋白的试剂的多核苷酸，以及包含编码细胞周期蛋白G1蛋白的多核苷酸的表达载体。
-
公开(公告)号：US06277369B1
公开(公告)日：2001-08-21
申请号：US09528696
申请日：2000-03-17
Applicant: Erlinda M. Gordon , W. French Anderson , Frederick L. Hall
Inventor： Erlinda M. Gordon , W. French Anderson , Frederick L. Hall
IPC: A61K4800
CPC classification number: C12N5/0663 , A61K48/00 , A61K2035/124 , C12N2501/15 , G01N2333/495
Abstract: A method for expressing a recombinant protein from bone marrow-derived cells comprises the steps of treating the bone marrow-derived cells in vitro with a TGF&bgr;1 protein, which selects a population of the cells for further treatment. The selected cells can then be expanded, after which a gene encoding a therapeutic protein can be inserted into the expanded cells and thereafter express the therapeutic protein. The transduced cells can then be introduced into a mammal to produce a therapeutic result.
Abstract translation: 用于从骨髓来源的细胞表达重组蛋白的方法包括以TGFbeta1蛋白体外处理骨髓来源的细胞的步骤，其选择细胞群进行进一步处理。 然后可以扩增选定的细胞，然后将编码治疗性蛋白质的基因插入扩增的细胞中，然后表达治疗性蛋白质。 然后将转导的细胞引入哺乳动物以产生治疗结果。
-
Patent Agency Ranking
6.发明授权Transgene delivering retrovirus targeting collagen exposed at site of tissue injury 失效转运基因导致组织损伤部位暴露的靶向胶原蛋白的逆转录病毒公开(公告)号：US08530441B2
公开(公告)日：2013-09-10
申请号：US13433615
申请日：2012-03-29
Applicant: Frederick L. Hall , Erlinda M. Gordon
Inventor： Frederick L. Hall , Erlinda M. Gordon
CPC classification number: C07K14/005 , A61K48/00 , C07K14/755 , C07K2319/00 , C07K2319/01 , C12N15/86 , C12N2740/13022 , C12N2740/13043 , C12N2740/13045 , C12N2810/857
Abstract: A viral or non-viral vector particle having a modified viral surface protein wherein the viral surface protein is modified to include a targeting polypeptide including a binding region which binds to an extracellular matrix component. Such vector particles are useful in delivering genes encoding therapeutic agents to cells located at the site of an exposed extracellular matrix component.
Abstract translation: 具有修饰的病毒表面蛋白质的病毒或非病毒载体颗粒，其中所述病毒表面蛋白被修饰为包括靶向多肽，所述靶向多肽包括结合细胞外基质组分的结合区域。 这样的载体颗粒可用于将编码治疗剂的基因递送至位于暴露的细胞外基质组分位点的细胞。
-
7.发明授权Transgene delivering retrovirus targeting collagen exposed at site of tissue injury 有权转运基因导致组织损伤部位暴露的靶向胶原蛋白的逆转录病毒公开(公告)号：US08148509B2
公开(公告)日：2012-04-03
申请号：US12879511
申请日：2010-09-10
Applicant: Frederick L. Hall , Erlinda M. Gordon
Inventor： Frederick L. Hall , Erlinda M. Gordon
CPC classification number: C07K14/005 , A61K48/00 , C07K14/755 , C07K2319/00 , C07K2319/01 , C12N15/86 , C12N2740/13022 , C12N2740/13043 , C12N2740/13045 , C12N2810/857
Abstract: A viral or non-viral vector particle having a modified viral surface protein wherein the viral surface protein is modified to include a targeting polypeptide including a binding region which binds to an extracellular matrix component. Such vector particles are useful in delivering genes encoding therapeutic agents to cells located at the site of an exposed extracellular matrix component.
Abstract translation: 具有修饰的病毒表面蛋白质的病毒或非病毒载体颗粒，其中所述病毒表面蛋白被修饰为包括靶向多肽，所述靶向多肽包括结合细胞外基质组分的结合区域。 这样的载体颗粒可用于将编码治疗剂的基因递送至位于暴露的细胞外基质组分位点的细胞。
-
8.发明授权公开(公告)号：US07795023B2
公开(公告)日：2010-09-14
申请号：US10404714
申请日：2003-03-31
Applicant: Frederick L. Hall , Erlinda M. Gordon
Inventor： Frederick L. Hall , Erlinda M. Gordon
CPC classification number: C12N5/0663 , A61K2035/124 , C12N5/0647 , C12N2500/42 , C12N2501/11 , C12N2501/125 , C12N2501/15 , C12N2501/23 , C12N2501/39 , C12N2510/00
Abstract: The present invention provides a molecular marker for the identification of pluripotent pre-mesenchymal, pre-hematopoietic stem cells. The invention further provides primitive progenitor cells identified by the molecular marker. Such cells have the potential to differentiate into both mesenchymal and hematopoietic phenotypes, as determined by a proliferative response to inductive growth factors and cytokines, and by their morphologic and cytochemical features.
Abstract translation: 本发明提供了用于鉴定多能前间充质干细胞的分子标记物。 本发明还提供了由分子标记鉴定的原始祖细胞。 这样的细胞具有分化成间充质和造血表型的潜力，如通过诱导生长因子和细胞因子的增殖反应以及其形态和细胞化学特征所确定的。
-
9.发明申请公开(公告)号：US20090123428A1
公开(公告)日：2009-05-14
申请号：US12235592
申请日：2008-09-22
Applicant: Frederick L. Hall , John P. Levy , Rebecca A. Reed , Erlinda M. Gordon
Inventor： Frederick L. Hall , John P. Levy , Rebecca A. Reed , Erlinda M. Gordon
CPC classification number: C12N15/86 , A01K67/0271 , A01K2207/15 , A01K2227/105 , A01K2267/0331 , A61K48/00 , C12N2740/13043 , C12N2740/13045 , C12N2740/13071 , C12N2810/6054 , C12N2810/857 , C12N2830/15
Abstract: Systems for pathotropic (disease-seeking) targeted gene delivery are provided, including viral particles with extremely high titers. In particular, the viral particles are engineered to specifically deliver therapeutic or diagnostic agents to a disease site, such as cancer metastic sites. Personalized dosing regimens are also provided to treat diseases such as cancer efficaciously with reduced adverse side effects.
Abstract translation: 提供用于致病性（寻疾）靶向基因递送的系统，包括具有极高滴度的病毒颗粒。 特别地，病毒颗粒被工程化以将治疗或诊断剂特异性递送到疾病部位，例如癌症转移部位。 还提供个性化的给药方案以有效地治疗诸如癌症的疾病，减少不良副作用。
-
公开(公告)号：US06387663B1
公开(公告)日：2002-05-14
申请号：US09127134
申请日：1998-07-31
Applicant: Frederick L. Hall , Erlinda M. Gordon , Vaughn A. Starnes , W. French Anderson
Inventor： Frederick L. Hall , Erlinda M. Gordon , Vaughn A. Starnes , W. French Anderson
IPC: C12P2104
CPC classification number: A01K67/0271 , A61K38/00 , A61K38/1866 , A61K48/00 , C07K14/755 , C07K2319/00 , C07K2319/21 , C07K2319/70 , C07K2319/75 , C12N15/62 , C12N2799/023 , A61K2300/00
Abstract: The present invention provides new compositions and methods to induce therapeutic angiogenesis locally utilizing a collagen binding domain to target an angiogenesis modulating agents. Fusion polypeptides containing a collagen binding domain linked to an angiogenesis modulating agent are provided, as are nucleic acid sequences encoding the fusion polypeptides. Also included are methods for locally altering circulation by administering a fusion polypeptide consisting of a collagen binding domain linked to an angiogenesis modulating agent, or by administering a nucleic acid sequences encoding the fusion polypeptide. Tissue grafts in which isolated tissue is treated with a fusion polypeptide consisting of a collagen binding domain linked to an angiogenesis modulating agent, or with a nucleic acid sequences encoding the fusion polypeptide are also provided, as are methods of making the grafts.
Abstract translation: 本发明提供了新的组合物和方法，其在局部利用胶原结合结构域靶向血管生成调节剂来诱导治疗性血管生成。 提供了与血管生成调节剂连接的含有胶原结合结构域的融合多肽，以及编码融合多肽的核酸序列。 还包括通过施用由与血管生成调节剂连接的胶原结合结构域组成的融合多肽或通过施用编码融合多肽的核酸序列来局部改变循环的方法。 还提供了组织移植物，其中分离的组织用由与血管生成调节剂连接的胶原结合结构域或与编码融合多肽的核酸序列组成的融合多肽处理，以及制备移植物的方法。
-
-
-
-
-
-
-
-
-
Search Results
33
records
(took 0.025 seconds)
